Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03969537 · ClinicalTrials.gov registry record

Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections

A clinical trial, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
27
Enrollment target

NCT03969537 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 27 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03969537 has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
27 participants
Enrollment target

Study Summary

Many cervical dystonia (CD) patients are limited in their ability to travel to the clinic for follow-up in between injection visits. A telemedicine visit at the time of peak effectiveness of neurotoxin treatment may be valuable in informing the neurologist's choice of muscle selection and/or dose for the next injection visit. The primary objective of this study is to investigate both patient and physician satisfaction with the use of our telemedicine tool for this type of follow-up. After assessment of the subject, the neurologist will decide whether or not the telemedicine visit was informative to the upcoming injection visit. Subjects will answer questions at the end of the visit regarding their satisfaction with the follow-up and overall telemedicine communication. The principle investigator will complete a similar survey with additional questions about information gathered from the visit to assess the primary objective. A secure video communications platform will be used for the visit, which will occur 2-4 weeks after the patient's last neurotoxin injection (around the time of peak effectiveness). The investigating neurologist will remotely assess the patient and make notes for the next injection visit.

Interventions

  • OTHER Telemedicine follow-up visit

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2019-04-01
Est. Completion 2020-06-04

What the Registry Record Tells You About NCT03969537

The ClinicalTrials.gov registry entry for NCT03969537 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Telemedicine follow-up visit is the first listed.

NCT03969537 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03969537 about?

NCT03969537 is a clinical study titled "Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections". Many cervical dystonia (CD) patients are limited in their ability to travel to the clinic for follow-up in between injection visits. A telemedicine visit at the time of peak effectiveness of neurotoxin treatment may be valuable in informing the neurologist's choice of muscle selection and/or dose f...

What is the current status of trial NCT03969537?

This trial is currently completed. The enrollment target is 27 participants. The study started on 2019-04-01. Estimated completion is 2020-06-04.

What interventions are being tested in trial NCT03969537?

The interventions under investigation include: Telemedicine follow-up visit (OTHER).

Who is sponsoring clinical trial NCT03969537?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.